Stocks Health care KALA
NASDAQ · Health careKALA BIO, Inc. (KALA)
It posted a net loss of $10.1M. At June 30, 2026 it held $229K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.
Key facts about KALA BIO, Inc.
- Net worth
- KALA BIO, Inc. has a market value (market cap) of $3.3M at the latest share price, and shareholders' equity of $9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $27M.
- Cash flow
- In fiscal 2025 operations used $32M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 19, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- KALA BIO, Inc.'s next report is expected around November 23, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What KALA BIO, Inc. does
KALA BIO, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KALA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$27M | -$3.31 | n/a |
| 2024 | $0 | -$38.5M | -$10.15 | n/a |
| 2023 | $0 | -$42.2M | -$17.35 | n/a |
| 2022 | $3.9M | -$44.8M | -$29.48 | n/a |
| 2021 | $11.2M | -$142.6M | -$108.32 | n/a |
| 2020 | $6.4M | -$104.3M | -$98.43 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What KALA BIO, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026Proxy statement DEF 14A
- September 11, 2026Preliminary proxy statement PRE 14A
- September 10, 2026
- September 9, 2026
- August 28, 2026
- August 19, 2026
- August 14, 2026Late quarterly report notice NT 10-Q
- July 23, 2026Other event 8-K
- July 2, 2026Activist stake changed SCHEDULE 13D/A
- June 12, 2026
Insider trades
What the people running KALA BIO, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns KALA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Oxford Finance LLC13G, passive | 16.5% | December 3, 2025 |
| ADAR1 Capital Management GP, LLC13G, passive with 2 related filers | 9.99% | November 14, 2024 |
| LifeSci Capital LLC13G, passive with 2 related filers | 7.9% | January 13, 2026 |
Largest institutional holders
Insiders
Questions about KALA
What does KALA BIO, Inc. do?
KALA BIO, Inc. is a company in the Health care sector, listed on NASDAQ as KALA. Its shares trade on NASDAQ under the ticker KALA.
What is KALA BIO, Inc.'s net worth?
KALA BIO, Inc. has a market value (market cap) of $3.3M at the latest share price, and shareholders' equity of $9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is KALA BIO, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.1M.
When did KALA BIO, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 24, 2026.
When is KALA BIO, Inc.'s next earnings report?
KALA BIO, Inc.'s next report is expected around November 23, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KALA with
Follow KALA
Get an email when KALA BIO, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values KALA BIO, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.